Site Editor

Soo Park, MD

Advertisement
Advertisement

ASCO 2024: Risk-Adapted Surgical De-escalation for Resectable Squamous Cell Carcinoma

By: Julia Cipriano, MS
Posted: Thursday, June 6, 2024

Rahul Ladwa, MBChB, BSc, FRACP, MPhil, of the University of Queensland, Brisbane, Australia, and colleagues evaluated a risk-adapted surgical de-escalation approach guided by clinical, radiologic, and pathologic responses in patients with resectable, locally advanced cutaneous squamous cell carcinoma who were undergoing neoadjuvant therapy with the PD-1 inhibitor pembrolizumab. The results of the multicenter phase II De-Squamate study were presented during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9514).

“Pembrolizumab led to a high rate of pathologic complete and clinical complete responses,” the investigators commented. “The study design effectively selected patients for surgical and postoperative radiation therapy de-escalation and demonstrated a sustained response in this cohort.”

A total of 27 immunocompetent patients with stage II to IV disease were treated with two to four cycles of 200 mg of intravenous pembrolizumab every 3 weeks. They underwent CT/MRI and 18F-fluorodeoxyglucose–PET imaging at baseline and after completing neoadjuvant therapy. In those with a complete metabolic response, mapping biopsies of the target sites were performed. A clinical complete response warranted omission of surgery and postoperative radiation therapy; patients with clinical or radiologic residual disease underwent surgical resection. Postoperative radiation therapy was de-escalated in the event of a pathologic complete or major pathologic response. The population received 13 cycles of maintenance therapy with pembrolizumab.

The combined pathologic complete, major pathologic, and clinical complete response rate was 63% (individually: 15%, 0%, and 48%, respectively). De-escalation of both surgery and postoperative radiation therapy was achieved in 48% of patients; an additional 15% avoided postoperative radiation therapy alone. With a minimum duration of follow-up of 6 months, none of the patients who achieved a pathologic complete, major pathologic, or clinical complete response experienced disease recurrence. Investigator-assessed treatment-related adverse events of grade 3 or higher were reported in 7% of the treated population.

Disclosure: For full disclosures of the study authors, visit coi.asco.org.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.